Literature DB >> 27347364

Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications.

Claire Edmondson1, Jane C Davies2.   

Abstract

Treatment for cystic fibrosis (CF) has conventionally targeted downstream consequences of the defect such as mucus plugging and infection. More recently, significant advances have been made in treating the root cause of the disease, namely a defective CF transmembrane conductance regulator (CFTR) gene. This review summarizes current pulmonary treatment options and highlights advances in research and development of new therapies.

Entities:  

Keywords:  CF transmembrane conductance regulator gene; cystic fibrosis; treatment

Year:  2016        PMID： 27347364      PMCID： PMC4907071          DOI： 10.1177/2040622316641352

Source DB:  PubMed          Journal:  Ther Adv Chronic Dis        ISSN： 2040-6223            Impact factor:   5.091


  84 in total

1.  Omalizumab: a new treatment option for allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.

Authors:  Sylvia Lehmann; Claus Pfannenstiel; Frank Friedrichs; Kristina Kröger; Norbert Wagner; Klaus Tenbrock
Journal:  Ther Adv Respir Dis       Date:  2014-08-21       Impact factor: 4.031

2.  Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial.

Authors:  D Elizabeth Tullis; Jane L Burns; George Z Retsch-Bogart; Mark Bresnik; Noreen R Henig; Sandra A Lewis; John J Lipuma
Journal:  J Cyst Fibros       Date:  2013-10-28       Impact factor: 5.482

3.  Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease.

Authors:  Kenneth N Olivier; Pamela A Shaw; Tanya S Glaser; Darshana Bhattacharyya; Michelle Fleshner; Carmen C Brewer; Christopher K Zalewski; Les R Folio; Jenifer R Siegelman; Shamira Shallom; In Kwon Park; Elizabeth P Sampaio; Adrian M Zelazny; Steven M Holland; D Rebecca Prevots
Journal:  Ann Am Thorac Soc       Date:  2014-01

Review 4.  Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis.

Authors:  Lesley Uttley; Sue Harnan; Anna Cantrell; Chris Taylor; Martin Walshaw; Keith Brownlee; Paul Tappenden
Journal:  Eur Respir Rev       Date:  2013-12

Review 5.  A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect.

Authors:  Michael P Boyle; Kris De Boeck
Journal:  Lancet Respir Med       Date:  2013-01-30       Impact factor: 30.700

Review 6.  Nebulized liposomal amikacin for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients.

Authors:  Zarmina Ehsan; Jacqueline Denise Wetzel; John P Clancy
Journal:  Expert Opin Investig Drugs       Date:  2014-03-05       Impact factor: 6.206

Review 7.  Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence.

Authors:  Kalliopi Tanou; Elias Zintzaras; Athanasios G Kaditis
Journal:  Pediatr Pulmonol       Date:  2013-10-25

8.  Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years.

Authors:  Don B Sanders; Aliza Fink; Nicole Mayer-Hamblett; Michael S Schechter; Gregory S Sawicki; Margaret Rosenfeld; Patrick A Flume; Wayne J Morgan
Journal:  J Pediatr       Date:  2015-09-02       Impact factor: 4.406

9.  Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Eitan Kerem; Michael W Konstan; Kris De Boeck; Frank J Accurso; Isabelle Sermet-Gaudelus; Michael Wilschanski; J Stuart Elborn; Paola Melotti; Inez Bronsveld; Isabelle Fajac; Anne Malfroot; Daniel B Rosenbluth; Patricia A Walker; Susanna A McColley; Christiane Knoop; Serena Quattrucci; Ernst Rietschel; Pamela L Zeitlin; Jay Barth; Gary L Elfring; Ellen M Welch; Arthur Branstrom; Robert J Spiegel; Stuart W Peltz; Temitayo Ajayi; Steven M Rowe
Journal:  Lancet Respir Med       Date:  2014-05-15       Impact factor: 30.700

Review 10.  Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.

Authors:  Simon C Langton Hewer; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2014-11-10
View more
  18 in total

1.  Treating Cystic Fibrosis with mRNA and CRISPR.

Authors:  Alejandro Da Silva Sanchez; Kalina Paunovska; Ana Cristian; James E Dahlman
Journal:  Hum Gene Ther       Date:  2020-09-08       Impact factor: 5.695

2.  Thickness of the airway surface liquid layer in the lung is affected in cystic fibrosis by compromised synergistic regulation of the ENaC ion channel.

Authors:  Daniel V Olivença; Luis L Fonseca; Eberhard O Voit; Francisco R Pinto
Journal:  J R Soc Interface       Date:  2019-08-28       Impact factor: 4.118

3.  Bone Marrow Transplantation Rescues Monocyte Recruitment Defect and Improves Cystic Fibrosis in Mice.

Authors:  Zhichao Fan; Elise Pitmon; Lai Wen; Jacqueline Miller; Erik Ehinger; Rana Herro; Wei Liu; Ju Chen; Zbigniew Mikulski; Douglas J Conrad; Alex Marki; Marco Orecchioni; Puja Kumari; Yanfang Peipei Zhu; Paola M Marcovecchio; Catherine C Hedrick; Craig A Hodges; Vijay A Rathinam; Kepeng Wang; Klaus Ley
Journal:  J Immunol       Date:  2022-01-14       Impact factor: 5.422

4.  Control the platelets, control the disease: A novel cystic fibrosis hypothesis.

Authors:  Siobhan Branfield; A Valance Washington
Journal:  J Thromb Haemost       Date:  2020-05-28       Impact factor: 5.824

Review 5.  Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis.

Authors:  N Mayer-Hamblett; D R VanDevanter
Journal:  Trends Mol Med       Date:  2020-08-28       Impact factor: 11.951

6.  Cyclic Peptidyl Inhibitors against CAL/CFTR Interaction for Treatment of Cystic Fibrosis.

Authors:  Patrick G Dougherty; Jack H Wellmerling; Amritendu Koley; Jessica K Lukowski; Amanda B Hummon; Estelle Cormet-Boyaka; Dehua Pei
Journal:  J Med Chem       Date:  2020-12-14       Impact factor: 7.446

Review 7.  Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review.

Authors:  Rosa María Girón Moreno; Marta García-Clemente; Layla Diab-Cáceres; Adrián Martínez-Vergara; Miguel Ángel Martínez-García; Rosa Mar Gómez-Punter
Journal:  Antibiotics (Basel)       Date:  2021-04-23

8.  Calcium Dysregulation in Alzheimer's Disease: A Target for New Drug Development.

Authors:  Yong Wang; Yun Shi; Huafeng Wei
Journal:  J Alzheimers Dis Parkinsonism       Date:  2017-09-15

9.  Targeting polyelectrolyte networks in purulent body fluids to modulate bactericidal properties of some antibiotics.

Authors:  Robert Bucki; Bonita Durnaś; Marzena Wątek; Ewelina Piktel; Katrina Cruz; Przemysław Wolak; Paul B Savage; Paul A Janmey
Journal:  Infect Drug Resist       Date:  2018-01-11       Impact factor: 4.003

10.  Evaluation of autophagy inducers in epithelial cells carrying the ΔF508 mutation of the cystic fibrosis transmembrane conductance regulator CFTR.

Authors:  Shaoyi Zhang; Gautier Stoll; José Manuel Bravo San Pedro; Valentina Sica; Allan Sauvat; Florine Obrist; Oliver Kepp; Yousheng Li; Luigi Maiuri; Naoufal Zamzami; Guido Kroemer
Journal:  Cell Death Dis       Date:  2018-02-07       Impact factor: 8.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.